Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
作者： Tor Henrik Tvedt , Ina Nepstad , Øystein Bruserud
DOI: 10.1080/13543784.2017.1275564
关键词:
摘要: ABSTRACTIntroduction: Midostaurin is a multikinase inhibitor that inhibits receptor tyrosine kinases (Flt3, CD117/c-kit, platelet-derived growth factor receptor, vascular endothelial 2) as well non-receptor (Frg, Src, Syk, Protein kinase C). Combination of midostaurin with conventional intensive chemotherapy followed by one year maintenance monotherapy was recently reported to improve the survival acute myeloid leukemia (AML) patients Flt3 mutations.Areas covered: Relevant publications were identified through literature searches in PubMed database. We searched for (i) original articles describing results from clinical studies; (ii) published importance midostaurin-inhibited leukemogenesis and chemosensitivity.Expert opinion: tolerated, combined gastrointestinal toxicity increases significantly. alters anthracycline pharmacokinetics. Fu...
sci-hub.se 参考文章(120)
Håkon Reikvam, Ina Nepstad, Øystein Bruserud, Kimberley Joanne Hatfield, Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget. ,vol. 4, pp. 830- 843 ,(2013) , 10.18632/ONCOTARGET.971
Øystein Bruserud, Line Wergeland, Randi Hovland, Tien-Sheng Huang, Bjørn Tore Gjertsen, Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities Haematologica. ,vol. 88, pp. 416- 428 ,(2003) , 10.3324/%X
Dylan T Jones, Atul B Mehta, H Grant Prentice, Kanagasabai Ganeshaguru, A Victor Hoffbrand, Katalin Csermak, Ranmohan G Wickremasinghe, Andres E Virchis, Kate Champain, Steve M Hart, Anthony Man, Mathew Gordon, Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. ,vol. 87, pp. 167- 176 ,(2002)
S LYMAN, H MCKENNA, CHAPTER 42 – Flt3 ligand The Cytokine Handbook (Fourth Edition). pp. 989- 1010 ,(2003) , 10.1016/B978-012689663-3/50046-6
Walter Fiedler, Ullrich Graeven, Süleyman Ergün, Sandra Verago, Nerbil Kilic, Marcus Stockschläder, Dieter K. Hossfeld, Vascular Endothelial Growth Factor, a Possible Paracrine Growth Factor in Human Acute Myeloid Leukemia Blood. ,vol. 89, pp. 1870- 1875 ,(1997) , 10.1182/BLOOD.V89.6.1870
CL Willman, CC Stewart, TL Longacre, DR Head, R Habbersett, SF Ziegler, RM Perlmutter, Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages Blood. ,vol. 77, pp. 726- 734 ,(1991) , 10.1182/BLOOD.V77.4.726.726
DC Link, M Zutter, The Proto-Oncogene c-fgr Is Expressed in Normal Mantle Zone B Lymphocytes and Is Developmentally Regulated During Myelomonocytic Differentiation In Vivo Blood. ,vol. 85, pp. 472- 479 ,(1995) , 10.1182/BLOOD.V85.2.472.472
Rashmi R. Shah, Joel Morganroth, Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit Drug Safety. ,vol. 38, pp. 693- 710 ,(2015) , 10.1007/S40264-015-0300-1
Peter Campochiaro, Stephan Bodis, Doriano Fabbro, Terence O'Reilly, Martin Pruschy, Jeanette Wood, Stephan Ruetz, Thomas Meyer, Katalin Csermak, Anthony Man, PKC412--a protein kinase inhibitor with a broad therapeutic potential. Anti-cancer Drug Design. ,vol. 15, pp. 17- 28 ,(2000)
H. Reikvam, A. M. Øyan, K. H. Kalland, R. Hovland, K. J. Hatfield, Ø. Bruserud, Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Proliferation. ,vol. 46, pp. 554- 562 ,(2013) , 10.1111/CPR.12057